Case Reports
doi: 10.3109/07357907.2013.775293.
Aggressive silent GH pituitary tumor resistant to multiple treatments, including temozolomide
Affiliations
- PMID: 23477586
- DOI: 10.3109/07357907.2013.775293
Item in Clipboard
Case Reports
Aggressive silent GH pituitary tumor resistant to multiple treatments, including temozolomide
Cancer Invest.
2013 Mar.
Abstract
Temozolomide (TMZ) has been proposed as a therapeutic option in aggressive pituitary tumors. Among the published cases, GH expressing tumors were rare. We describe a patient with initially benign silent GH adenoma that transformed into an aggressive GH secreting tumor resistant to usual therapy. MGMT expression was high and the MGMT promoter was unmethylated. Before this aggressive course, patient received three cycles of TMZ; no response was observed. Four cases of GH aggressive tumor treated by TMZ have been reported. Response to TMZ was observed in one of these four patients. Predictive factors of failure of TMZ remain unclear.
Similar articles
-
The role of temozolomide in the treatment of aggressive pituitary tumors.J Clin Neurosci. 2015 Jun;22(6):923-9. doi: 10.1016/j.jocn.2014.12.007. Epub 2015 Mar 12. J Clin Neurosci. 2015. PMID: 25772801 Review.
-
Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide.J Clin Endocrinol Metab. 2015 Apr;100(4):1689-98. doi: 10.1210/jc.2014-4350. Epub 2015 Feb 3. J Clin Endocrinol Metab. 2015. PMID: 25646794
-
MGMT immunoexpression in growth hormone-secreting pituitary adenomas and its correlation with Ki-67 labeling index and cytokeratin distribution pattern.Endocrine. 2011 Oct;40(2):222-7. doi: 10.1007/s12020-011-9485-y. Epub 2011 May 15. Endocrine. 2011. PMID: 21792693
-
A mechanism of acquiring temozolomide resistance during transformation of atypical prolactinoma into prolactin-producing pituitary carcinoma: case report.Neurosurgery. 2011 Jun;68(6):E1761-7; discussion E1767. doi: 10.1227/NEU.0b013e318217161a. Neurosurgery. 2011. PMID: 21389894
-
Treatment of pituitary neoplasms with temozolomide: a review.Cancer. 2011 Feb 1;117(3):454-62. doi: 10.1002/cncr.25413. Epub 2010 Sep 15. Cancer. 2011. PMID: 20845485 Review.
Cited by
-
Phenotype Transformation of PitNETs.Cancers (Basel). 2024 Apr 29;16(9):1731. doi: 10.3390/cancers16091731. Cancers (Basel). 2024. PMID: 38730682 Free PMC article. Review.
-
Multidisciplinary management of difficult/aggressive growth-hormone pituitary neuro-endocrine tumors.Front Endocrinol (Lausanne). 2023 May 3;14:1123267. doi: 10.3389/fendo.2023.1123267. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37206441 Free PMC article. Review.
-
Temozolomide and Capecitabine Treatment for an Aggressive Somatotroph Pituitary Tumor: A Case Report and Literature Review.Front Oncol. 2022 May 26;12:916982. doi: 10.3389/fonc.2022.916982. eCollection 2022. Front Oncol. 2022. PMID: 35712496 Free PMC article.
-
High-risk pituitary adenomas and strategies for predicting response to treatment.Hormones (Athens). 2022 Mar;21(1):1-14. doi: 10.1007/s42000-021-00333-y. Epub 2022 Jan 21. Hormones (Athens). 2022. PMID: 35061210 Review.
-
MGMT assessment in pituitary adenomas: comparison of different immunohistochemistry fixation chemicals.Pituitary. 2018 Jun;21(3):266-273. doi: 10.1007/s11102-018-0862-x. Pituitary. 2018. PMID: 29344904 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
